The Cytokine Release Syndrome Management Market Size is valued at USD 23.1 billion in 2023 and is predicted to reach USD 36.8 billion by the year 2031 at a 6.2% CAGR during the forecast period for 2024-2031.
Management of Cytokine Release Syndrome (CRS) entails regulating a severe immune response that may arise during treatments such as CAR T-cell therapy. Hence, the adoption of Cytokine Release Syndrome Management is expected to increase in the near future as concerns grow over the treatment and technological advancement. Growing adoption of Cytokine release syndrome management due to an increase in the prevalence of the disease and a rise in healthcare expenses are factors expected to drive the growth of the global Cytokine Release Syndrome Management market. Additionally, technological advancement and modernization in the healthcare sector and the rising demand from developing economies in various industries are some of the other factors expected to augment the target market growth. The increasing number of the aged population globally is expected to boost the market expansion in the coming years.
However, the high cost of Cytokine Release Syndrome Management and ineffective treatment, coupled with the COVID-19 outbreak, are factors that may affect the growth of the target market during the forecast period. Furthermore, increasing R&D activities, government initiatives and promotions to use sustainable components for production, and investments by key players are factors expected to create lucrative development opportunities in terms of revenue for players operating in the global Cytokine Release Syndrome Management market over the forecast period.
The Cytokine Release Syndrome Management market is segmented on the basis of cytokine type, therapeutic application, biomarker type, route of administration, and end user. Based on cytokine type, the market is segmented as Tumor Necrosis Factor-TNF, Interleukins-II, Interfernos-IFN, and Epidermal Growth Faator-EGF. As per the Therapeutic application, the market is segmented into Cancer, Asthma, Airway Inflammation, Arthritis, and Others. The Biomarker Type segment includes Interleukin-10, Interferon Gamma, Interleukin-6, Ferritin, and Cluster of Differentiation-163. The Route of Administration segment consists of Oral and Intravenous. By End User, the market is segmented into Hospitals, Specialty Clinics, and Others.
The Tumor Necrosis Factor-TNF category is expected to hold a major share in the global Cytokine Release Syndrome Management market in 2023. This is attributed to growing new technologies and rising awareness. The usage of therapy is rising as a direct result of cytokine release syndrome, which is an adverse reaction linked with cancer treatments.
The arthritis therapeutics segment is projected to grow at a rapid rate in the global Cytokine Release Syndrome Management market owing to the growing aged population. Hence, the increasing aging population with lifestyle factors like obesity and sedentary habits contributes to the rising incidence of arthritis globally.
The North American cytokine release syndrome management market is expected to record the very large market revenue share in the near future. This can be attributed to the rising cancer cases and other chronic diseases in the region, with the increasing adoption of Cytokine Release Syndrome Management for the treatment. In addition, small-molecule drugs and novel monoclonal antibodies in the region focus on the adoption of Cytokine Release Syndrome Management. In addition, the European regionis projected to grow rapidly in the global Cytokine Release Syndrome Management market due to the growing acceptance of immunotherapy for treating solid tumours.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 23.1 Bn |
|
Revenue Forecast In 2031 |
USD 36.8 Bn |
|
Growth Rate CAGR |
CAGR of 6.2% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Cytokine Type, Therapeutic Application, Biomarker Type, Route Of Administration, And End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
F.Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Novartis AG, Sanofi S.A, Pfizer Inc., Bayer AG, Biocon, AbbVie Inc., Johnson & Johnson Private Limited, Incyte Corporation, Swedish Orphan Biovitrum, and Genentech. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cytokine Release Syndrome Management Market Snapshot
Chapter 4. Global Cytokine Release Syndrome Management Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Cytokine Release Syndrome Management Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Cytokine Release Syndrome Management Industry Trends
Chapter 5. Cytokine Release Syndrome Management Market Segmentation 1: By Cytokine Type, Estimates & Trend Analysis
5.1. Market Share by Cytokine Type, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Cytokine Type
5.2.1. Tumor Necrosis Factor-TNF
5.2.2. Interleukins-II
5.2.3. Interferons-IFN
5.2.4. Epidermal Growth Factor-EGF
Chapter 6. Cytokine Release Syndrome Management Market Segmentation 2: By Therapeutic Application, Estimates & Trend Analysis
6.1. Market Share by Therapeutic Application, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Therapeutic Applications:
6.2.1. Cancer
6.2.2. Asthma
6.2.3. Airway Inflammation
6.2.4. Arthritis
6.2.5. Others
Chapter 7. Cytokine Release Syndrome Management Market Segmentation 3: By Biomarker Type, Estimates & Trend Analysis
7.1. Market Share by Biomarker Type, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Biomarker Type:
7.2.1. Interleukin-10
7.2.2. Interferon Gamma
7.2.3. Interleukin-6
7.2.4. Ferritin
7.2.5. Cluster of Differentiation-163
Chapter 8. Cytokine Release Syndrome Management Market Segmentation 4: By Route of Administration, Estimates & Trend Analysis
8.1. Market Share by Route of Administration, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
Chapter 9. Cytokine Release Syndrome Management Market Segmentation 5: By End User, Estimates & Trend Analysis
9.1. Market Share by End User, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End User:
9.2.1. Hospitals
9.2.2. Specialty Clinics
9.2.3. Others
Chapter 10. Cytokine Release Syndrome Management Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Cytokine Release Syndrome Management Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Cytokine Type, 2024-2031
10.2.3. North America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Application, 2024-2031
10.2.4. North America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Type, 2024-2031
10.2.5. North America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.2.6. North America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.3. Europe
10.3.1. Europe Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Cytokine Type, 2024-2031
10.3.3. Europe Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Application, 2024-2031
10.3.4. Europe Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Type, 2024-2031
10.3.5. Europe Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.3.6. Europe Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Cytokine Type, 2024-2031
10.4.3. Asia Pacific Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Application, 2024-2031
10.4.4. Asia Pacific Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Type, 2024-2031
10.4.5. Asia Pacific Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
10.4.6. Asia Pacific Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.5. Latin America
10.5.1. Latin America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Cytokine Type, 2024-2031
10.5.3. Latin America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Application, 2024-2031
10.5.4. Latin America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Type, 2024-2031
10.5.5. Latin America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.5.6. Latin America Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Cytokine Type, 2024-2031
10.6.3. Middle East & Africa Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Application, 2024-2031
10.6.4. Middle East & Africa Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Type, 2024-2031
10.6.5. Middle East & Africa Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.6.6. Middle East & Africa Cytokine Release Syndrome Management Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. F. Hoffmann-La Roche Ltd
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. GlaxoSmithKline Plc
11.2.3. Novartis AG
11.2.4. Sanofi S.A
11.2.5. Pfizer Inc.
11.2.6. Bayer AG
11.2.7. Biocon
11.2.8. AbbVie Inc.
11.2.9. Johnson & Johnson Private Limited
11.2.10. Incyte Corporation
11.2.11. Swedish Orphan Biovitrum
11.2.12. Genentech
11.2.13. Other Prominent Players
Cytokine Release Syndrome Management Market By Cytokine Type-
Cytokine Release Syndrome Management Market By Therapeutic Application-
Cytokine Release Syndrome Management Market By Biomarker Type-
Cytokine Release Syndrome Management Market By Route of Administration-
Cytokine Release Syndrome Management Market By End User-
Cytokine Release Syndrome Management Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
